این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Pediatric Hematology and Oncology، جلد ۱۳، شماره ۲، صفحات ۹۹-۱۱۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Synergistic Anti-Cancer Effects of Second-Generation Proteasome Inhibitor Carfilzomib with Doxorubicin and Dexamethasone Via p53-Mediated Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cells
چکیده انگلیسی مقاله Background: The ubiquitin-proteasome system (UPS) plays a crucial role in regulating the levels and functions of a large number of proteins in the cell, which are important for cancer cell growth and survival. The proteasome is highly activated in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), which is the most common malignancy in children. The attempt to inhibit proteasome as a therapeutic strategy has been successful for some malignancies. Materials and Methods: In this experimental study, human BCP-ALL cell lines NALM-6 and SUP-B15 were treated with carfilzomib with and without the chemotherapeutic agents. The XTT assay evaluated the viability of the cells. Cell cycle analysis and apoptosis assay were assessed by flow cytometry. RQ-PCR and western blotting evaluated the expression of pro-/anti-apoptotic signals. A drug combination study for synergistic or additive effects of carfilzomib with doxorubicin or dexamethasone was performed. Results: We observed that carfilzomib alone induced G2/M cell cycle arrest and caspase-dependent apoptosis in the human BCP-ALL cells (NALM-6 and SUP-B15). Gene and protein expression analysis indicated the upregulation of pro-apoptotic as well as downregulation of the cell survival and proliferative signals (P-value< 0.05). The synergy of carfilzomib with doxorubicin or dexamethasone was revealed in BCP-ALL cells. Conclusion: Our results indicated that proteasome inhibition induces p53-mediated apoptosis in BCP-ALL cells. Since carfilzomib has a synergistic effect with anti-leukemic agents doxorubicin and dexamethasone in BCP-ALL cells, this combined-modality approach might be befitting for patients who do not respond well to conventional chemotherapy.
کلیدواژه‌های انگلیسی مقاله Acute lymphoblastic leukemia, Carfilzomib, Dexamethasone, Doxorubicin, Proteasome
نویسندگان مقاله | Ali Amini
Department of Hematology and Blood Banking Faculty of Allied Medicine Iran University of Medical Sciences


| Mohammad Faranoush
Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran


| Mostafa Paridar
Ministry of Health and Medical Education, Deputy of Management and Resources Development, Tehran, Iran


| Ahmad Kazemi
Department of Hematology and Blood Banking Faculty of Allied Medicine Iran University of Medical Sciences


| Mohammad Reza Rezvani
Department of Hematology and Blood Banking Faculty of Allied Medicine Iran University of Medical Sciences


| Majid Safa
Department of Hematology and Blood Banking Faculty of Allied Medicine Iran University of Medical Sciences
نشانی اینترنتی http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-954-1&slc_lang=en&sid=1
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده قلب
نوع مقاله منتشر شده پژوهشی
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات